Tempus AI今日盘中大涨7.11%，引起了市场的广泛关注。
消息面上，Tempus AI近日宣布与吉利德科学签署扩展的多年期合作协议，以支持后者肿瘤学管线的开发。根据协议，吉利德将获得Tempus AI旗下AI驱动的Lens平台的企业级访问权限，可在多个适应症中更广泛地使用去标识化的多模态数据集。该合作的深化进一步验证了Tempus AI在精准医疗领域的平台价值，提振了市场情绪。
此外，据FactSet统计，分析师对Tempus AI的平均评级为“超配”，平均目标价为72.40美元，显著高于当前股价，尽管Jefferies近期以35美元目标价给予“跑输大盘”评级，但整体市场共识仍偏乐观，这也为股价提供了支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.